{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:00:02Z","timestamp":1770742802824,"version":"3.49.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":86,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacepopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACEP Open"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1002\/emp2.13265","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T06:48:47Z","timestamp":1724654927000},"page":"e13265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emergency department management of opioid use disorder in pediatric patients"],"prefix":"10.1016","volume":"5","author":[{"given":"Evan S.","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann M","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Sandelich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwen","family":"Hooley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Ruttan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin L.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Sulton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7914-8993","authenticated-orcid":false,"given":"Jessica","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1002\/emp2.13265_bb0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archpediatrics.2012.85","article-title":"Medical and nonmedical use of prescription opioids among high school seniors in the United States","volume":"166","author":"McCabe","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1002\/emp2.13265_bb0015","series-title":"Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration","article-title":"Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17\u20135044, NSDUH Series H\u201052)","year":"2017"},{"key":"10.1002\/emp2.13265_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108584","article-title":"Trends and age\u2010related disparities in opioid use disorder treatment admissions for adolescents and young adults","volume":"132","author":"Welsh","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"10.1002\/emp2.13265_bb0025","article-title":"Management of adolescents with OUD: a simulation case for subspecialty trainees in addiction medicine and addiction psychiatry","volume":"17","author":"Garcia\u2010Vassallo","year":"2021","journal-title":"MedEdPORTAL"},{"key":"10.1002\/emp2.13265_bb0030","unstructured":"Diagnostic and statistical manual of mental disorders: DSM\u20105\u2122, 5th ed, Diagnostic and statistical manual of mental disorders: DSM\u20105\u2122, 5th ed.(2013)."},{"issue":"5","key":"10.1002\/emp2.13265_bb0035","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/jcpt.13114","article-title":"Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management","volume":"45","author":"Pergolizzi","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1002\/emp2.13265_bb0040","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/CNQ.0000000000000262","article-title":"Clinical opioid withdrawal scale (COWS): implementation and outcomes","volume":"42","author":"Canamo","year":"2019","journal-title":"Crit Care Nurs Q"},{"key":"10.1002\/emp2.13265_bb0045","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ajem.2021.06.026","article-title":"Pediatric opioid\u2010related emergency visits offer critical opportunities for opioid safety screening and planning","volume":"55","author":"Love","year":"2022","journal-title":"Am J Emerg Med"},{"key":"10.1002\/emp2.13265_bb0050","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.genhosppsych.2020.10.002","article-title":"Literature review: substance use screening and co\u2010morbidity in medically hospitalized youth","volume":"67","author":"Smith","year":"2020","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1002\/emp2.13265_bb0055","unstructured":"Screening and Treatment of Substance Use Disorders among Adolescents. Advisory. Publication No. PEP20\u201006\u201004\u2010008. Substance Abuse and Mental Health Services Administration.;2021."},{"issue":"1","key":"10.1002\/emp2.13265_bb0060","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1211","article-title":"Substance use screening, brief intervention, and referral to treatment","volume":"138","author":"Levy","year":"2016","journal-title":"Pediatrics"},{"key":"10.1002\/emp2.13265_bb0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jsat.2015.10.006","article-title":"SBIRT\u2010A: adapting SBIRT to maximize developmental fit for adolescents in primary care","volume":"62","author":"Ozechowski","year":"2016","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"10.1002\/emp2.13265_bb0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.17294\/2330-0698.1656","article-title":"Confidential care for adolescents in the U.S. health care system","volume":"6","author":"Pathak","year":"2019","journal-title":"J Patient Cent Res Rev"},{"issue":"2","key":"10.1002\/emp2.13265_bb0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0035-1556749","article-title":"Pediatric withdrawal identification and management","volume":"4","author":"Whelan","year":"2015","journal-title":"J Pediatr Intensive Care"},{"issue":"3","key":"10.1002\/emp2.13265_bb0080","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.chc.2016.03.002","article-title":"Opioid use disorders","volume":"25","author":"Sharma","year":"2016","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"1\u20102","key":"10.1002\/emp2.13265_bb0085","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.drugalcdep.2009.07.001","article-title":"Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single\u2010item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument","volume":"105","author":"Tompkins","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1002\/emp2.13265_bb0090","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The Clinical Opiate Withdrawal Scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoactive Drugs"},{"issue":"6","key":"10.1002\/emp2.13265_bb0095","article-title":"Emergency department\u2010initiated buprenorphine protocols: a national evaluation","volume":"2","author":"Guo","year":"2021","journal-title":"J Am Coll Emerg Physicians Open"},{"issue":"8","key":"10.1002\/emp2.13265_bb0100","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/add.13363","article-title":"A randomized controlled trial of buprenorphine taper duration among opioid\u2010dependent adolescents and young adults","volume":"111","author":"Marsch","year":"2016","journal-title":"Addiction"},{"issue":"2","key":"10.1002\/emp2.13265_bb0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1002\/emp2.13265_bb0110","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0376-8716(03)00058-9","article-title":"Pharmacokinetics of the combination tablet of buprenorphine and naloxone","volume":"70","author":"Chiang","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1002\/emp2.13265_bb0115","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1002\/emp2.13265_bb0120","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1517\/17425247.2012.729574","article-title":"Buprenorphine and buprenorphine\/naloxone soluble\u2010film for treatment of opioid dependence","volume":"9","author":"Soyka","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"10.1002\/emp2.13265_bb0125","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1517\/17425247.2014.953479","article-title":"Buprenorphine\u2010naloxone buccal soluble film for the treatment of opioid dependence: current update","volume":"12","author":"Soyka","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1002\/emp2.13265_bb0130","volume":"2024","year":"2023"},{"issue":"4","key":"10.1002\/emp2.13265_bb0135","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/acps.13088","article-title":"Reduction in mortality risk with opioid agonist therapy: a systematic review and meta\u2010analysis","volume":"140","author":"Bahji","year":"2019","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"10.1002\/emp2.13265_bb0140","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.annemergmed.2018.11.032","article-title":"Managing opioid withdrawal in the emergency department with buprenorphine","volume":"73","author":"Herring","year":"2019","journal-title":"Ann Emerg Med"},{"issue":"8","key":"10.1002\/emp2.13265_bb0145","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/add.14188","article-title":"The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom","volume":"113","author":"Hickman","year":"2018","journal-title":"Addiction"},{"issue":"10","key":"10.1002\/emp2.13265_bb0150","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","article-title":"Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study","volume":"2","author":"Kimber","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"9776","key":"10.1002\/emp2.13265_bb0155","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended\u2010release naltrexone for opioid dependence: a double\u2010blind, placebo\u2010controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"issue":"10118","key":"10.1002\/emp2.13265_bb0160","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended\u2010release naltrexone versus buprenorphine\u2010naloxone for opioid relapse prevention (X:bOT): a multicentre, open\u2010label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/emp2.13265_bb0165","article-title":"Opioid substitution treatment is linked to reduced risk of death in opioid use disorder","volume":"357","author":"Manhapra","year":"2017","journal-title":"Bmj"},{"key":"10.1002\/emp2.13265_bb0170","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta\u2010analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"Bmj"},{"issue":"12","key":"10.1002\/emp2.13265_bb0175","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended\u2010release naltrexone vs daily buprenorphine\u2010naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1002\/emp2.13265_bb0180","article-title":"Medication\u2010assisted treatment of adolescents with opioid use disorders","volume":"138","year":"2016","journal-title":"Pediatrics"},{"issue":"3","key":"10.1002\/emp2.13265_bb0185","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jadohealth.2020.12.129","article-title":"Medication for adolescents and young adults with opioid use disorder","volume":"68","year":"2021","journal-title":"J Adolesc Health"},{"issue":"3","key":"10.1002\/emp2.13265_bb0190","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/ADM.0000000000000388","article-title":"Buprenorphine treatment for adolescents and young adults with opioid use disorders: a narrative review","volume":"12","author":"Borodovsky","year":"2018","journal-title":"J Addict Med"},{"issue":"6","key":"10.1002\/emp2.13265_bb0195","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jadohealth.2016.12.023","article-title":"Medication\u2010assisted treatment for adolescents in specialty treatment for opioid use disorder","volume":"60","author":"Feder","year":"2017","journal-title":"J Adolesc Health"},{"issue":"2","key":"10.1002\/emp2.13265_bb0200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40124-018-0161-z","article-title":"Opioid use disorders in adolescents\u2010updates in assessment and management","volume":"6","author":"Yule","year":"2018","journal-title":"Curr Pediatr Rep"},{"issue":"2","key":"10.1002\/emp2.13265_bb0205","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-058755","article-title":"Buprenorphine dispensing among youth aged \u226419 years in the United States: 2015\u20132020","volume":"151","author":"Terranella","year":"2023","journal-title":"Pediatrics"},{"issue":"2","key":"10.1002\/emp2.13265_bb0210","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1542\/hpeds.2022-006864","article-title":"A novel inpatient buprenorphine induction program for adolescents with opioid use disorder","volume":"13","author":"Trope","year":"2023","journal-title":"Hosp Pediatr"},{"issue":"10","key":"10.1002\/emp2.13265_bb0215","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archpsyc.62.10.1157","article-title":"Comparison of pharmacological treatments for opioid\u2010dependent adolescents: a randomized controlled trial","volume":"62","author":"Marsch","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"17","key":"10.1002\/emp2.13265_bb0220","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.2008.574","article-title":"Extended vs short\u2010term buprenorphine\u2010naloxone for treatment of opioid\u2010addicted youth: a randomized trial","volume":"300","author":"Woody","year":"2008","journal-title":"Jama"},{"issue":"5","key":"10.1002\/emp2.13265_bb0225","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/phar.2676","article-title":"Buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review","volume":"42","author":"Spreen","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1002\/emp2.13265_bb0230","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/ajad.13135","article-title":"Microinduction of buprenorphine\/naloxone: a review of the literature","volume":"30","author":"Ahmed","year":"2021","journal-title":"Am J Addict"},{"issue":"4","key":"10.1002\/emp2.13265_bb0235","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/ADM.0000000000000945","article-title":"Low dose initiation of buprenorphine: a narrative review and practical approach","volume":"16","author":"Cohen","year":"2022","journal-title":"J Addict Med"},{"issue":"5","key":"10.1002\/emp2.13265_bb0240","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40261-021-01032-7","article-title":"The pharmacology of buprenorphine microinduction for opioid use disorder","volume":"41","author":"De Aquino","year":"2021","journal-title":"Clin Drug Investig"},{"key":"10.1002\/emp2.13265_bb0245","unstructured":"Facher L. Fentanyl isn't just causing overdoses. It's making it harder to start addiction treatment. STAT. November 16, 2022."},{"issue":"8","key":"10.1002\/emp2.13265_bb0250","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/ajad.12809","article-title":"Methadone to buprenorphine\/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting\u2010Azar method","volume":"27","author":"Azar","year":"2018","journal-title":"Am J Addict"},{"issue":"4","key":"10.1002\/emp2.13265_bb0255","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/ADM.0000000000000947","article-title":"Low dose buprenorphine induction with full agonist overlap in hospitalized patients with opioid use disorder: a retrospective cohort study","volume":"16","author":"Bhatraju","year":"2022","journal-title":"J Addict Med"},{"issue":"5","key":"10.1002\/emp2.13265_bb0260","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/dar.13113","article-title":"Use of a novel prescribing approach for the treatment of opioid use disorder: buprenorphine\/naloxone micro\u2010dosing\u2014a case series","volume":"39","author":"Brar","year":"2020","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"10.1002\/emp2.13265_bb0265","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1097\/ADM.0000000000000864","article-title":"Low\u2010dose buprenorphine initiation in hospitalized adults with opioid use disorder: a retrospective cohort analysis","volume":"16","author":"Button","year":"2022","journal-title":"J Addict Med"},{"issue":"5","key":"10.1002\/emp2.13265_bb0270","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1097\/ADM.0000000000000618","article-title":"Rapid transition from methadone to buprenorphine utilizing a micro\u2010dosing protocol in the outpatient veteran affairs setting","volume":"14","author":"De Aquino","year":"2020","journal-title":"J Addict Med"},{"issue":"4","key":"10.1002\/emp2.13265_bb0275","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/08897077.2021.1915914","article-title":"Rapid buprenorphine microdosing for opioid use disorder in a hospitalized patient receiving very high doses of full agonist opioids for acute pain management: titration, implementation barriers, and strategies to overcomes","volume":"42","author":"DeWeese","year":"2021","journal-title":"Subst Abus"},{"issue":"6","key":"10.1002\/emp2.13265_bb0280","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/ADM.0000000000000675","article-title":"Rapid micro\u2010induction of buprenorphine\/naloxone for opioid use disorder in a critically ill intubated patient: a case report","volume":"14","author":"Hamata","year":"2020","journal-title":"J Addict Med"},{"key":"10.1002\/emp2.13265_bb0285","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/SAR.S109919","article-title":"Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method","volume":"7","author":"H\u00e4mmig","year":"2016","journal-title":"Subst Abuse Rehabil"},{"issue":"4","key":"10.1002\/emp2.13265_bb0290","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ajad.12869","article-title":"Rapid micro\u2010induction of buprenorphine\/naloxone for opioid use disorder in an inpatient setting: a case series","volume":"28","author":"Klaire","year":"2019","journal-title":"Am J Addict"},{"issue":"2","key":"10.1002\/emp2.13265_bb0295","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1213\/XAA.0000000000001138","article-title":"Rapid induction of buprenorphine\/naloxone for chronic pain using a microdosing regimen: a case report","volume":"14","author":"Lee","year":"2020","journal-title":"A A Pract"},{"issue":"3","key":"10.1002\/emp2.13265_bb0300","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/10550887.2021.1996153","article-title":"Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine\/naloxone in an outpatient setting\u2010a case report","volume":"40","author":"Martell","year":"2022","journal-title":"J Addict Dis"},{"issue":"4","key":"10.1002\/emp2.13265_bb0305","first-page":"35","article-title":"Case report:\u201cstriving to skip the withdrawal\u201d using buprenorphine\u2013naloxone microdosing for hospitalized patients","volume":"10","author":"Martin","year":"2019","journal-title":"Can J Addict"},{"issue":"6","key":"10.1002\/emp2.13265_bb0310","doi-asserted-by":"crossref","first-page":"369","DOI":"10.9740\/mhc.2021.11.369","article-title":"Microdose induction of buprenorphine\u2010naloxone in a patient using high dose methadone: a case report","volume":"11","author":"Menard","year":"2021","journal-title":"Ment Health Clin"},{"issue":"4","key":"10.1002\/emp2.13265_bb0315","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1108\/DAT-04-2016-0011","article-title":"Substitution of heroin and methadone with buprenorphine using an overlap method without needing to wait for withdrawal","volume":"16","author":"Payler","year":"2016","journal-title":"Drugs Alcohol Today"},{"issue":"24","key":"10.1002\/emp2.13265_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph192416436","article-title":"Buprenorphine microdosing cross tapers: a time for change","volume":"19","author":"Raheemullah","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"10.1002\/emp2.13265_bb0325","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13722-020-0177-x","article-title":"Case report: successful induction of buprenorphine\/naloxone using a microdosing schedule and assertive outreach","volume":"15","author":"Rozylo","year":"2020","journal-title":"Addict Sci Clin Pract"},{"issue":"10","key":"10.1002\/emp2.13265_bb0330","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/phar.2313","article-title":"Transitioning hospitalized patients with opioid use disorder from methadone to buprenorphine without a period of opioid abstinence using a microdosing protocol","volume":"39","author":"Terasaki","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1002\/emp2.13265_bb0335","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13722-021-00220-2","article-title":"Comparing rapid micro\u2010induction and standard induction of buprenorphine\/naloxone for treatment of opioid use disorder: protocol for an open\u2010label, parallel\u2010group, superiority, randomized controlled trial","volume":"16","author":"Wong","year":"2021","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"10.1002\/emp2.13265_bb0340","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28766","article-title":"Ambulatory microdose induction of buprenorphine\u2010naloxone in two adolescent patients with sickle cell disease","volume":"68","author":"Buchheit","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1002\/emp2.13265_bb0345","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ajad.13050","article-title":"A case report: rapid micro\u2010induction of buprenorphine\/naloxone to administer buprenorphine extended\u2010release in an adolescent with severe opioid use disorder","volume":"29","author":"Azar","year":"2020","journal-title":"Am J Addict"},{"issue":"7","key":"10.1002\/emp2.13265_bb0350","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High\u2010dose buprenorphine induction in the emergency department for treatment of opioid use disorder","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1002\/emp2.13265_bb0355","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1526-4637.2002.02047.x","article-title":"Methadone reincarnated: novel clinical applications with related concerns","volume":"3","author":"Fishman","year":"2002","journal-title":"Pain Med"},{"key":"10.1002\/emp2.13265_bb0360","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/14659890410001665078","article-title":"Methadone matters, evolving community methadone treatment of opiate addiction Gillian Tober and John Strang Martin Dunitz","volume":"9","author":"Pates","year":"2004","journal-title":"J Subst Use"},{"key":"10.1002\/emp2.13265_bb0365","series-title":"5, Federal Regulation of Methadone Treatment","article-title":"Federal regulation of methadone treatment","year":"1995"},{"issue":"13","key":"10.1002\/emp2.13265_bb0370","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jama.2019.12562","article-title":"Drive times to opioid treatment programs in urban and rural counties in 5 US states","volume":"322","author":"Joudrey","year":"2019","journal-title":"Jama"},{"key":"10.1002\/emp2.13265_bb0375","unstructured":"Federal Guidelines for Opioid Treatment Programs. HHS Publication No. (SMA) XX\u2010XXXX. Substance Abuse and Mental Health Services Administration: Substance Abuse and Mental Health Services Administration; 2015. https:\/\/store.samhsa.gov\/sites\/default\/files\/guidelines-opioid-treatment-pep15-fedguideotp.pdf"},{"issue":"2","key":"10.1002\/emp2.13265_bb0380","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0740-5472(02)00259-3","article-title":"History and current status of opioid maintenance treatments: blending conference session","volume":"23","author":"Kreek","year":"2002","journal-title":"J Subst Abuse Treat"},{"key":"10.1002\/emp2.13265_bb0385","unstructured":"SAMHSA. (2015, January 26). CIB: Coverage of Behavioral Health Services for Youth with Substance Use Disorders [press release]. Joint CMCS and SAMHSA Informational Bulletin. 2015. Accessed on August 9, 2024. https:\/\/www.medicaid.gov\/federal-policyguidance\/downloads\/cib-01-26-2015.pdf"},{"issue":"1","key":"10.1002\/emp2.13265_bb0390","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/00952990.2022.2106574","article-title":"Open\u2010label, rapid initiation pilot study for extended\u2010release buprenorphine subcutaneous injection","volume":"49","author":"Hassman","year":"2023","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"3","key":"10.1002\/emp2.13265_bb0395","article-title":"Incidence of precipitated withdrawal during a multisite emergency department\u2010initiated buprenorphine clinical trial in the era of fentanyl","volume":"6","author":"D'Onofrio","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1002\/emp2.13265_bb0400","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.ajem.2019.05.053","article-title":"Rapid induction onto sublingual buprenorphine after opioid overdose and successful linkage to treatment for opioid use disorder","volume":"37","author":"Herring","year":"2019","journal-title":"Am J Emerg Med"},{"issue":"4","key":"10.1002\/emp2.13265_bb0405","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/dar.13228","article-title":"Managing opioid withdrawal precipitated by buprenorphine with buprenorphine","volume":"40","author":"Oakley","year":"2021","journal-title":"Drug Alcohol Rev"},{"issue":"7b","key":"10.1002\/emp2.13265_bb0410","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0028-3908(87)90054-2","article-title":"Common alpha 2\u2010 and opiate effector mechanisms in the locus coeruleus: intracellular studies in brain slices","volume":"26","author":"Aghajanian","year":"1987","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1002\/emp2.13265_bb0415","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0376-8716(00)00139-3","article-title":"Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes","volume":"61","author":"Elman","year":"2001","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1002\/emp2.13265_bb0420","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0024-3205(95)02294-5","article-title":"Diazepam pretreatment suppresses morphine withdrawal signs in the mouse","volume":"58","author":"Suzuki","year":"1996","journal-title":"Life Sci"},{"issue":"3","key":"10.1002\/emp2.13265_bb0425","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/ACO.0000000000000865","article-title":"The opioid epidemic in pediatrics: a 2020 update","volume":"33","author":"Yaster","year":"2020","journal-title":"Curr Opin Anaesthesiol"},{"issue":"1","key":"10.1002\/emp2.13265_bb0430","first-page":"72","article-title":"Opioid use in children","volume":"24","author":"Matson","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"10.1002\/emp2.13265_bb0435","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jadohealth.2019.07.009","article-title":"Availability of naloxone in pharmacies and knowledge of pharmacy staff regarding dispensing naloxone to younger adolescents","volume":"65","author":"Jimenez","year":"2019","journal-title":"J Adolesc Health"}],"container-title":["JACEP Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2688115224014334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2688115224014334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/emp2.13265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T11:27:41Z","timestamp":1738754861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2688115224014334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2688115224014334"],"URL":"https:\/\/doi.org\/10.1002\/emp2.13265","relation":{},"ISSN":["2688-1152"],"issn-type":[{"value":"2688-1152","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emergency department management of opioid use disorder in pediatric patients","name":"articletitle","label":"Article Title"},{"value":"JACEP Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/emp2.13265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"e13265"}}